ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P76-22 No-Load Miles (Deadhead) Reimbursement Rate for Minnesota Health Care Programs Subscribers
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါဒံၣ်စဲဘၢၣ် 01, 2022
လံာ်တီလံာ်မီတဖၣ်ဒီး လံာ်ကွီၣ်ဒိတဖၣ်အစၢတဖၣ်
တၢ်ပာ်ဖျါ 1471 - 1480 လၢ 3563 အစၢတဖၣ်အကျါ
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P77-22 New Medical, Medical Drug and Behavioral Health Policy Management Updates: Effective January 30, 2023
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါဖ့ၤဘြူၤအါရံၤ 01, 2023
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
bc-com-pharm-prog-policy-notifctn-11.30.22-eff-1.15.23-final.pdf
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P75-22 Update to 2023 Renewal Changes Summaries for BP PCC & Institutional Providers
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါဒံၣ်စဲဘၢၣ် 01, 2022
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
upcoming-policies-effective-january-30-2023.pdf
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP99-22 Commercial Pharmacy Benefit Update: Revised Drug-Related Prior Authorization (PA) Requirement Notification, Effective January 15, 2023
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါနိၣ်၀့ဘၢၣ် 23, 2022
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP98-22 Commercial Pharmacy Benefit Exclusion for Cimerli™, Skysona®, Spevigo®, and Xenpozyme™
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါနိၣ်၀့ဘၢၣ် 23, 2022
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP97-22 Update for New to Market Medical Drugs: etranacogene dezaparvovec
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါနိၣ်၀့ဘၢၣ် 23, 2022
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP100-22 Service Area Expansion for Minnesota Health Care Programs (MHCP)
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါနိၣ်၀့ဘၢၣ် 23, 2022
ကသံၣ်ထံလဲ ဒီး ကသံၣ်ကျး
KeyRx Drug List Alternatives Effective October 2022